4D Molecular Therapeutics, Inc.
FDMT
$4.21
-$0.075-1.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.00K | 17.00K | 20.22M | 20.45M | 20.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.00K | 17.00K | 20.22M | 20.45M | 20.72M |
| Cost of Revenue | 141.30M | 124.24M | 110.82M | 102.55M | 97.09M |
| Gross Profit | -141.26M | -124.23M | -90.61M | -82.10M | -76.37M |
| SG&A Expenses | 46.58M | 44.15M | 40.61M | 38.80M | 36.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 187.88M | 168.39M | 151.44M | 141.35M | 133.59M |
| Operating Income | -187.84M | -168.38M | -131.22M | -120.90M | -112.87M |
| Income Before Tax | -160.87M | -143.48M | -109.89M | -104.56M | -100.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.87 | -143.48 | -109.89 | -104.56 | -100.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.87M | -143.48M | -109.89M | -104.56M | -100.84M |
| EBIT | -187.84M | -168.38M | -131.22M | -120.90M | -112.87M |
| EBITDA | -183.19M | -163.72M | -126.76M | -116.55M | -108.66M |
| EPS Basic | -2.97 | -2.83 | -2.29 | -2.43 | -2.64 |
| Normalized Basic EPS | -1.86 | -1.77 | -1.43 | -1.52 | -1.65 |
| EPS Diluted | -2.97 | -2.83 | -2.29 | -2.43 | -2.64 |
| Normalized Diluted EPS | -1.86 | -1.77 | -1.43 | -1.52 | -1.65 |
| Average Basic Shares Outstanding | 215.75M | 202.98M | 189.68M | 172.73M | 156.18M |
| Average Diluted Shares Outstanding | 215.75M | 202.98M | 189.68M | 172.73M | 156.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
